The Clinical Cost of Delays in Switching TherapyReportar como inadecuado

The Clinical Cost of Delays in Switching Therapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Canadian Journal of Infectious Diseases and Medical Microbiology - Volume 18 2007, Suppl A, Pages 5A-7A

Division of Infectious Diseases, Department of Medicine, University of Toronto, and Toronto General Hospital, Toronto, Ontario, Canada

Copyright © 2007 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Management of the HIV patient with treatment experience continues to improve and evolve. New guidelines suggest that the goal of therapy should be maximal virological suppression. This is best achieved by using combinations of agents to which the virus is most likely to have some susceptibility and, where possible, by using agents within a new therapeutic class. The cases discussed demonstrate how the use of a potent regimen as salvage therapy can have good clinical, immunological and virological outcomes. However, if the salvage regimen selected is not potent enough to achieve these goals, the durability of the response is limited. The key lesson is that these strategies should be built on potency and agents should not be held back in case the strategy fails.

Autor: Sharon Walmsley



Documentos relacionados